20101 results for «»
20101 results
Thivya V Vadiveloo
Liverpool, United Kingdom
Michela Pittaluga
GENOVA, Italy
Santiago Garcia

Maria Tafesse
Karlskrona, Sweden
Joshua Hon
London, United Kingdom
Jack Stewart
Belfast, United Kingdom
1-year SELUTION DeNovo results: what they mean for daily practice
29 Oct 2025
The SELUTION DeNovo trial, presented by Christian Spaulding at TCT 2025, delivers the first head-to-head comparison between a sirolimus DCB strategy and contemporary DES in PCI.
In this review, Salvatore Brugaletta breaks down the 1-year results and what these findings truly mean for everyday lesion-by-lesion decision-making.

Author

Author

Author
Vincent Pham
PARIS, France
Fabio Fazzari
Milan, Italy
Severin Laengle
Vienna, Austria
Kakeru Ishihara
Gifu, Japan
Caglayan Demirel
Wien, Austria
DES and DCB for bifurcation treatment
21 May 2025 – From EuroPCR 2025
Examine the use of drug-eluting stents (DES) and drug-coated balloons (DCB) in bifurcation lesion treatment. This session compares devices, analyses DAPT duration, and evaluates side branch optimization to inform best practices in bifurcation PCI.
Management of stent-related complications
21 May 2025 – From EuroPCR 2025
This session addresses the management of stent-related complications through a series of dramatic clinical cases. Learn methodical approaches to routine and crisis scenarios including primary PCI complications, failure to stent, and unexpected challenges encountered during interventions, highlighting practical bailout techniques and decision-making frameworks.
TAV-in-TAV complications
21 May 2025 – From EuroPCR 2025
Focus on the complexities and challenges of TAV-in-TAV procedures in this session. Topics include planning valve-in-valve TAVI for aortic bioprosthetic valve regurgitation, managing anatomical challenges such as left ventricular outflow tract calcium and large annulus, and addressing severe bicuspid valve stenosis with impaired ventricular function. The...
Iatrogenic causes for shock treated with LV support
21 May 2025 – From EuroPCR 2025
Explore the management of iatrogenic causes of cardiogenic shock requiring left ventricular support. This session presents complex cases including shock following Bentall procedures, complications during anesthesia induction in bypass surgery, and strategic approaches to prevent and manage these critical scenarios using LV support devices.
Major Late-Breaking Trials from EuroPCR 2025
21 May 2025 – From EuroPCR 2025
Discover major late-breaking trials from EuroPCR 2025 in this session presenting pivotal study data. Highlights include meta-analyses from the PROTECTED TAVR and BHF PROTECT-TAVI studies, angiography versus physiology-guided PCI during TAVI (FAITAVI trial), and novel antiplatelet strategies following drug-coated stent implantation in acute coronary syndrome, with...
Treatment dilemmas in STEMI patients with multivessel disease
21 May 2025 – From EuroPCR 2025
Address treatment dilemmas in STEMI patients with multivessel disease through this session focused on imaging and physiology-guided revascularisation strategies. Learn optimal approaches for cases with CABG indications, and timing considerations for non-culprit vessel revascularisation during hospital admission or later stages, supported by illustrative clinical cases.
Stent technologies, last evidence in coronary interventions
21 May 2025 – From EuroPCR 2025
Update your knowledge on the latest stent technologies and clinical evidence in coronary interventions. This session reviews long-term outcomes of resorbable magnesium scaffolds, seven-year data from the COMPARE-ABSORB trial, bioadaptor versus stent comparisons, dual therapy sirolimus-eluting versus biolimus-eluting stents, and randomized trials on direct stenting versus...
Coronary scaffolds: new developments and applications
21 May 2025 – From EuroPCR 2025
Stay informed on advancements in coronary scaffolds with this session reviewing new developments and applications. Topics include comparative performance of magnesium-based bioresorbable stents, long-term clinical outcomes from the BIOMAG-I and FANTOM BRS studies, and real-world experiences with next-generation thin-strut scaffolds.